3 Forgotten Small-Caps Cashing In on AI, Box Office, and Nuclear

The market is in full distraction mode: Iran, blockades, bond yields screaming. While everyone is doom-scrolling Reuters, a few genuinely interesting small-cap setups are sitting right there, unnoticed. Here are three picks that showed up in this week's social sentiment data with actual reasons to pay attention.

1. Photronics ($PLAB) - Semiconductor Photomasks, Market Cap ~$1.5B

$PLAB makes the photomasks used to print semiconductor circuits, which means it sits upstream of every chip fab expansion happening right now. As Bloomberg's Ankur Crawford pointed out this week, her edge as a former Intel engineer is understanding exactly which picks-and-shovels names benefit most from AI chip buildouts without the headline risk. Photronics is about as picks-and-shovels as it gets: no matter which foundry wins the AI chip race, they need photomasks. The company posted revenue of $906M in its most recent fiscal year, trading at roughly 10x forward earnings, which is almost offensively cheap for a company with zero AI exposure narrative risk. The catalyst: Intel's US fab ramp and TSMC Arizona production scaling both require significantly more advanced photomasks. Nobody on CNBC is saying the word Photronics. That is kind of the point.

2. IMAX Corporation ($IMAX) - Premium Cinema Tech, Market Cap ~$1.4B

$IMAX is having a quietly spectacular 2026. This week's Bloomberg podcast on Hollywood's box office revival was explicit: premium formats like IMAX and 70mm are the primary driver of the theatrical recovery, with fresh IP and returning franchises outperforming the tired cinematic universe model. IMAX earns a revenue share on every ticket sold globally in its network, plus upfront fees for new screen installations. The bear case is simple: streaming exists. The bull case is that IMAX is essentially the only format that genuinely cannot be replicated at home, and the content slate through Q4 looks strong. The company has been aggressively expanding in India and China, two markets where theatrical attendance is structurally growing. With attendance recovering and ticket price mix shifting toward premium, IMAX margins expand faster than revenue, a dynamic the market has been slow to reprice.

3. BWX Technologies ($BWXT) - Nuclear Components, Market Cap ~$8.5B

$BWXT manufactures nuclear reactors and components for the US Navy and is the only US company licensed to make naval nuclear reactors. This week, Modi's Independence Day speech announced India's target of 100 gigawatts of nuclear capacity, eleven times current levels, alongside eight new semiconductor fabs. Data center buildouts globally need power that renewables alone cannot provide on the required timeline, and nuclear is the answer everyone is suddenly taking seriously. BWXT is not a pure-play on India directly, but it is the dominant US supplier of the kind of small modular reactor and naval reactor technology that underpins every serious Western nuclear expansion conversation. The stock is up but has not gone parabolic the way some nuclear pure-plays have. It has an actual moat: you cannot just build a competing naval reactor supplier. The catalyst is a formal SMR procurement announcement from any major hyperscaler, which multiple Bloomberg analysts flagged as increasingly likely before year-end.

Three completely different sectors, three completely different catalysts. The only thing they share is that nobody on financial Twitter is making memes about any of them, which in 2026 is practically a buy signal on its own.